期刊文献+

注射用烟酰胺药品不良反应分析 被引量:6

Adverse drug reactions induced by nicotinamide for injection
下载PDF
导出
摘要 目的分析注射用烟酰胺药品不良反应(ADR)发生的特点和规律,促进临床合理用药。方法对2018年1月—2020年12月河南省上报国家药品不良反应监测系统的80例注射用烟酰胺药品不良反应进行分析。结果共计纳入ADR病例80例,其中新的ADR 28例(35.00%),50岁以上66例(82.50%),29例(36.25%)存在超适应证用药,49例(61.25%)ADR发生于输注过程中,ADR累及系统/器官以皮肤及其附件、全身性反应、消化系统、神经系统、心血管系统最常见。结论临床药师应掌握注射用烟酰胺ADR发生特点,提醒医师严格按照说明书要求用药,用药过程中密切监护,减少ADR对患者造成的损害。 Objective To analyze the general information and clinical characteristics of adverse drug reactions(ADR)induced by nicotinamide for injection to promote rational drug use.Methods Totally 80 reported ADRs in Henan Province between January 2018 and December 2020 were analyzed retrospectively.Results Totally 80 cases were collected,among which 28(35.00%)were new ADRs,66(82.50%)over 50 years old,29(36.25%)with off-label use,and 49(61.25%)occurred in the course of intravenous infusion.Injury of the skin,systematic injury,digestive system,nervous system,and cardiovascular system were the common clinical manifestations.Conclusion Clinical pharmacists should be aware of the characteristics of ADR induced by nicotinamide for injection,which should be used strictly in accordance with the instructions and monitored closely during the course of nicotinamide injection to reduce possible injuries to patients.
作者 景天闯 张丹 范晶晶 魏简汇 冯文华 JING Tian-chuang;ZHANG Dan;FAN Jing-jing;WEI Jian-hui;FENG Wen-hua(Nanyang Central Hospital,Nanyang Henan 473000;Nanyang Institute of Food and Drug Control,Nanyang Henan 473000)
出处 《中南药学》 CAS 2021年第8期1725-1728,共4页 Central South Pharmacy
基金 河南省医学科技攻关计划联合共建项目(No.LHGJ20191459)。
关键词 注射用烟酰胺 药品不良反应 合理用药 药学监护 nicotinamide adverse drug reaction rational drug use pharmaceutical care
  • 相关文献

参考文献5

二级参考文献20

  • 1李诚让,朱文元.维生素C衍生物研究进展[J].临床皮肤科杂志,2005,34(7):487-488. 被引量:12
  • 2Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease[J]. J Am Soc Nephrol, 2005, 16(2): 520-528. 被引量:1
  • 3Kong X, Zhang L, Zhang L, et al. Mineral and bone disorder in Chinese dialysis patients: a multicenter study[J]. BMC Nephrol, 2012, 13(9): 1-7. 被引量:1
  • 4Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium- based versus non- calcium- based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta- analysis[J]. Lancet, 2013, 382 (9900): 1268-1277. 被引量:1
  • 5Lenglet A, Liabeuf S, Guffroy P, et al. Use of nicotinamide to treat hyperphosphatemia in dialysis patients[J]. Drugs RD, 2013, 13(3): 165-173. 被引量:1
  • 6Depner TA, Daugirdas JT. Equations for normalized protein catabolic rate based on two- point modeling of hemodialysis urea kinetics[J]. J Am Soc Nephrol, 1996, 7(5): 780-785. 被引量:1
  • 7Sehiavi SC, Tang W, Bracken C, et al. Npt2b deletion attenuates hyperphosphatemia associated with CKD[J]. J Am Soc Nephrol, 2012, 23(10): 1691-1700. 被引量:1
  • 8Eto N, Miyata Y, Ohno H, et al. Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine- induced renal failure[J]. Nephrol Dial Transplant, 2005, 20(7): 1378-1384. 被引量:1
  • 9Knip M, Douek iF, Moore WP, et al. Safety of high- dose nicotinamide: a review[J]. Diabetologia, 2000, 43(11): 1337- 1345. 被引量:1
  • 10TT OBTSJN. Nicotinic acid- induced toxicity associated with cytopenia and decreased levels of thyroxine- binding globulin [J]. Mayo Clin Proe, 1992, 67(5): 465-468. 被引量:1

共引文献13

同被引文献67

引证文献6

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部